$100 BILLION BURNS HOLE IN DRUG FIRMS' POCKETS

Big pharma's appetite for biotech deals, already fueled by a need to supplement weakened pipelines and replace products coming off patent, is expected to surge this year as a handful of companies seek to reinvest nearly $100 billion in repatriated profits.
MSNBC